Servier and MiNA Therapeutics sign 220m deal
French Servier SA and the UKs MiNA Therapeutics Ltd have entered into a R&D partnership to identify and develop small activating RNAs (saRNA) to treat neurological disorders.
LSP leads 21m round into Neurent Medical
Irish life sciences company Neurent Medical has closed a 21m Series B investment co-led by LSP as well as Atlantic Bridge with participation of Fountain Healthcare Partners.
Janssen presents one-shot COVID-19 vaccine data
J&J subsidiary Janssen Pharma has presented updated Phase I/II antibody levels supporting a single shot administration for its COVID-19 vaccine.
German researchers find reason for remdesivir’s inefficiency
German Researchers have unraveled how remdesivir interferes with the viral RNA polymerase and why it does not block SARS-CoV-2 completely.
LSP reports first closing of dementia fund
European life sciences investors LSP has closed a new fund to fight dementia at 50m.
Valneva in talks with EU about 60 million vaccine doses
French Valneva SE announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine, VLA2001.
Immunocore bags US$75m in Series C round
Immuno-oncology specialist Immunocore plc announced the completion of a $75m Series C private financing round.
EU approves second COVID-19 vaccine
Following a recommendation by the European Medicines Agency (EMA), the European Commission has approved a second vaccine against the novel coronavirus SARS-CoV-2.
Angelini Pharma to take over Arvelle Therapeutics
Italian Angelini Pharma and Swiss CNS disease specialist Arvelle Therapeutics have entered into a definitive merger agreement.
COVID-19 test gives results within minutes
University of Birmingham researchers have invented a COVID-19 RNA test that reduces testing time from 30 minutes to under five, and delivers accurate results.